Emerging therapeutic targets of sepsis-associated acute kidney injury

Seminars in Nephrology
Sundararaman SwaminathanMark D Okusa

Abstract

Sepsis-associated acute kidney injury (SA-AKI) is linked to high morbidity and mortality. To date, singular approaches to target specific pathways known to contribute to the pathogenesis of SA-AKI have failed. Because of the complexity of the pathogenesis of SA-AKI, a reassessment necessitates integrative approaches to therapeutics of SA-AKI that include general supportive therapies such as the use of vasopressors, fluids, antimicrobials, and target-specific and time-dependent therapeutics. There has been recent progress in our understanding of the pathogenesis and treatment of SA-AKI including the temporal nature of proinflammatory and anti-inflammatory processes. In this review, we discuss the clinical and experimental basis of emerging therapeutic approaches that focus on targeting early proinflammatory and late anti-inflammatory processes, as well as therapeutics that may enhance cellular survival and recovery. Finally, we include ongoing clinical trials in sepsis.

References

Apr 1, 1989·Baillière's Clinical Haematology·J M Gutteridge, B Halliwell
Sep 14, 1972·The New England Journal of Medicine·L Thomas
Oct 9, 1998·Transactions of the Royal Society of Tropical Medicine and Hygiene·P E ThumaV R Gordeuk
Dec 6, 2001·American Journal of Respiratory and Critical Care Medicine·H WangK J Tracey
Oct 10, 2002·Kidney International·Timothy A SuttonBruce A Molitoris
Jan 10, 2003·The New England Journal of Medicine·Richard S Hotchkiss, Irene E Karl
Sep 17, 2003·The Journal of Clinical Investigation·Yuan-Ji DayMark D Okusa
Jan 30, 2004·Immunobiology·Bernd EchtenacherDaniela N Männel
Mar 24, 2004·International Immunopharmacology·Evangelos MessarisManousos M Konstadoulakis
Nov 9, 2004·Trends in Pharmacological Sciences·Rainer H Straub
Nov 18, 2004·International Journal of Molecular Medicine·Maria Beatriz HerreraGiovanni Camussi
Feb 17, 2005·American Journal of Physiology. Renal Physiology·Florian TögelChristof Westenfelder
Apr 9, 2005·American Journal of Physiology. Renal Physiology·Shenyang LiDidier Portilla
May 3, 2005·Nature Reviews. Immunology·Thomas W Klein
Jul 29, 2005·American Journal of Physiology. Renal Physiology·Brian PooleRobert Schrier
Aug 18, 2005·JAMA : the Journal of the American Medical Association·Shigehiko UchinoUNKNOWN Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators
Oct 8, 2005·Nature Medicine·Ernest A McCulloch, James E Till
Dec 1, 2005·Kidney International·Kiran K NagothuDidier Portilla
Feb 18, 2006·Critical Care Medicine·Reimar W ThomsenHans-Henrik Lervang
Jun 30, 2006·Trends in Immunology·Emma M Creagh, Luke A J O'Neill
Aug 23, 2006·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Satoshi Uematsu, Shizuo Akira
Aug 26, 2006·Nature Clinical Practice. Nephrology·Li Li, Mark D Okusa
Oct 6, 2006·Expert Opinion on Pharmacotherapy·Jean-Louis Vincent
Jan 11, 2007·American Journal of Physiology. Renal Physiology·Florian TögelChristof Westenfelder
Jul 14, 2007·Nature Reviews. Immunology·Adrian E Morelli, Angus W Thomson
Jul 28, 2007·Journal of the American Society of Nephrology : JASN·Baoyuan BiLloyd G Cantley
Apr 1, 2008·Experimental Biology and Medicine·Kun Wang, Yu-Jui Yvonne Wan
Oct 1, 2008·Critical Care Medicine·Ryan ZarychanskiAnand Kumar
Nov 26, 2008·Circulation Research·Massimiliano GnecchiVictor J Dzau
Jan 30, 2009·Journal of the American Society of Nephrology : JASN·Asif A SharfuddinBruce A Molitoris
Feb 24, 2009·Current Opinion in Immunology·Tomas Ganz
Feb 27, 2009·Critical Care Medicine·Fabián JaimesAlvaro Muñoz
Apr 25, 2009·Journal of the American Society of Nephrology : JASN·Stefania BrunoGiovanni Camussi
Apr 29, 2009·Journal of Cellular and Molecular Medicine·Florian TögelChristof Westenfelder
May 12, 2009·The Journal of Infection·Quan-Hui YangXiao-Ting Wang
Jun 6, 2009·Journal of the American Society of Nephrology : JASN·Gilbert R KinseyMark D Okusa
Aug 8, 2009·Critical Care Medicine·Mark TidswellUNKNOWN Eritoran Sepsis Study Group

❮ Previous
Next ❯

Citations

Mar 16, 2016·Critical Care : the Official Journal of the Critical Care Forum·Sergio DellepianeVincenzo Cantaluppi
Oct 30, 2016·Jornal de pediatria·Prasad Devarajan, Rajit K Basu
Dec 10, 2017·Journal of the American Society of Nephrology : JASN·Maria A BattistoneSylvie Breton
Feb 27, 2016·Scientific Reports·Shuqin MeiZheng Dong
Mar 11, 2016·American Journal of Physiology. Renal Physiology·Nataliya I SkrypnykMark P de Caestecker
Oct 5, 2018·Toxicologic Pathology·Zaher A Radi
Jan 24, 2018·World Journal of Nephrology·Maria-Eleni RoumeliotiAntonios H Tzamaloukas
Mar 9, 2019·International Journal of Toxicology·Zaher A Radi
Jul 28, 2019·Cannabis and Cannabinoid Research·Janice T ChuaHamid Moradi
Apr 16, 2021·Acta Biochimica Et Biophysica Sinica·Ni YangZhengliang Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Blood Coagulation Signaling Pathways

Coagulation is the process by which a blood clot is formed. This process includes both the formation of a platelet plug as well as a cascade of clotting factors resulting in the formation of fibrin strands. Find the latest research on coagulation signaling pathways here.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Autophagy & Model Organisms

Autophagy is a cellular process that allows degradation by the lysosome of cytoplasmic components such as proteins or organelles. Here is the latest research on autophagy & model organisms

Autophagy & Disease

Autophagy is an important cellular process for normal physiology and both elevated and decreased levels of autophagy are associated with disease. Here is the latest research.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Related Papers

Seminars in Nephrology
Rashid AlobaidiSean M Bagshaw
Journal of the National Medical Association
R B DODD
© 2021 Meta ULC. All rights reserved